Q&A with Model N's Michael Grosberg drills deeper into the new US drug pricing directives, including challenges in ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine explains how insights from the ...

Results from the Phase IIIb FRONTIER5 trial demonstrated that Mim8 prophylaxis was well-tolerated when administered without a ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company partners with patient advocacy groups to identify unmet needs and prioritize patient-centered benefits in the ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

The label update for Amyvid adds guidance for assessing amyloid plaque levels and may help inform diagnostic and treatment ...